Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy

REP 2139 is a nucleic acid polymer (NAP) currently under clinical development for chronic hepatitis B (HBV) therapy. This preclinical study investigated different REP 2139 analogs that would display reduced accumulation in the serum and tissues, while retaining an antiviral effect against HBV infect...

Descripción completa

Detalles Bibliográficos
Autores principales: Roehl, Ingo, Seiffert, Stephan, Brikh, Celia, Quinet, Jonathan, Jamard, Catherine, Dorfler, Nadine, Lockridge, Jennifer A., Cova, Lucyna, Vaillant, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466589/
https://www.ncbi.nlm.nih.gov/pubmed/28918011
http://dx.doi.org/10.1016/j.omtn.2017.04.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466589/
https://www.ncbi.nlm.nih.gov/pubmed/28918011
http://dx.doi.org/10.1016/j.omtn.2017.04.019

Ejemplares similares